<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Heart J</journal-id><journal-id journal-id-type="iso-abbrev">Eur. Heart J</journal-id><journal-id journal-id-type="publisher-id">eurheartj</journal-id><journal-id journal-id-type="hwp">ehj</journal-id><journal-title-group><journal-title>European Heart Journal</journal-title></journal-title-group><issn pub-type="ppub">0195-668X</issn><issn pub-type="epub">1522-9645</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22930458</article-id><article-id pub-id-type="pmc">3485575</article-id><article-id pub-id-type="doi">10.1093/eurheartj/ehs290</article-id><article-id pub-id-type="publisher-id">ehs290</article-id><article-categories><subj-group subj-group-type="heading"><subject>Esc Fasttrack</subject><subj-group subj-group-type="heading"><subject>ESC hot line</subject></subj-group></subj-group><series-title>Fast Track</series-title></article-categories><title-group><article-title>Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac
surgery without atrial ablation in patients with coronary and/or valvular heart disease
plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre
study<sup><xref ref-type="author-notes" rid="AN1">&#x02020;</xref></sup></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Budera</surname><given-names>Petr</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Straka</surname><given-names>Zbyn&#x0011b;k</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Osman&#x0010d;&#x000ed;k</surname><given-names>Pavel</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Van&#x0011b;k</surname><given-names>Tom&#x000e1;&#x00161;</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jel&#x000ed;nek</surname><given-names>&#x00160;t&#x0011b;p&#x000e1;n</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hlavi&#x0010d;ka</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fojt</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>&#x0010c;ervinka</surname><given-names>Pavel</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hulman</surname><given-names>Michal</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>&#x00160;m&#x000ed;d</surname><given-names>Michal</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mal&#x000fd;</surname><given-names>Marek</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Widimsk&#x000fd;</surname><given-names>Petr</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Cardiocenter, Third Faculty of Medicine</addr-line>,
<institution>Charles University Prague</institution>, <country>Czech
Republic</country></aff><aff id="af2"><label>2</label><addr-line>Cardiology Department</addr-line>,
<institution>Masaryk Hospital</institution>, <addr-line>Usti nad Labem</addr-line>,
<country>Czech Republic</country></aff><aff id="af3"><label>3</label><institution>National Institute of Cardiovascular
Diseases</institution>, <addr-line>Bratislava</addr-line>,
<country>Slovakia</country></aff><aff id="af4"><label>4</label><addr-line>Cardiocenter, Faculty of Medicine in
Pilsen</addr-line>, <country>Charles University Prague, Czech Republic</country></aff><aff id="af5"><label>5</label><institution>National Institute of Public Health</institution>,
<addr-line>Prague</addr-line>, <country>Czech Republic</country></aff><author-notes><corresp id="cor1"><label>*</label>Corresponding author: Department of Cardiac
Surgery, Kr&#x000e1;lovsk&#x000e9; Vinohrady University Hospital, &#x00160;rob&#x000e1;rova
50, 100 34 Prague 10, Czech Republic. Tel: +420 26716 3255, Fax: +420 26716
3260, Email: <email>budera@atlas.cz</email></corresp><fn id="AN1"><label>&#x02020;</label><p>The results were presented at the ESC Congress Hot Line session III on 28 August
2012.</p></fn></author-notes><pub-date pub-type="ppub"><month>11</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>28</day><month>8</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>8</month><year>2012</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>33</volume><issue>21</issue><fpage>2644</fpage><lpage>2652</lpage><history><date date-type="received"><day>5</day><month>8</month><year>2012</year></date><date date-type="rev-recd"><day>5</day><month>8</month><year>2012</year></date><date date-type="accepted"><day>9</day><month>8</month><year>2012</year></date></history><permissions><copyright-statement>Published on behalf of the European Society of Cardiology. All rights
reserved. &#x000a9; The Author 2012.</copyright-statement><copyright-year>2012</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons
Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>),
which permits unrestricted non-commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="ehs290.pdf"/><related-article id="d35e256" related-article-type="article-reference" ext-link-type="doi" xlink:href="10.1093/eurheartj/ehs294"/><abstract><sec><title>Aims</title><p>Surgical ablation procedure can restore sinus rhythm (SR) in patients with atrial
fibrillation (AF) undergoing cardiac surgery. However, it is not known whether it has
any impact on long-term clinical outcomes.</p></sec><sec><title>Methods and results</title><p>This multicentre study randomized 224 patients with AF scheduled for valve and/or
coronary surgery: group A (left atrial surgical ablation, <italic>n</italic> =
117) vs. group B (no ablation, <italic>n</italic> = 107). The primary efficacy
outcome was the SR presence (without any AF episode) during a 24 h electrocardiogram
(ECG) after 1 year. The primary safety outcome was the combined endpoint of
death/myocardial infarction/stroke/renal failure at 30 days. A Holter-ECG after 1 year
revealed SR in 60.2% of group A patients vs. 35.5% in group B
(<italic>P</italic> = 0.002). The combined safety endpoint at 30 days occurred
in 10.3% (group A) vs. 14.7% (group B, <italic>P</italic> = 0.411).
All-cause 1-year mortality was 16.2% (A) vs. 17.4% (B, <italic>P</italic>
= 0.800). Stroke occurred in 2.7% (A) vs. 4.3% (B) patients
(<italic>P</italic> = 0.319). No difference (A vs. B) in SR was found among
patients with paroxysmal (61.9 vs. 58.3%) or persistent (72 vs. 50%) AF,
but ablation significantly increased SR prevalence in patients with longstanding
persistent AF (53.2 vs. 13.9%, <italic>P</italic> &#x0003c; 0.001).</p></sec><sec><title>Conclusion</title><p>Surgical ablation improves the likelihood of SR presence post-operatively without
increasing peri-operative complications. However, the higher prevalence of SR did not
translate to improved clinical outcomes at 1 year. Further follow-ups (e.g. 5-year) are
warranted to show any potential clinical benefit which might occur later.</p></sec></abstract><kwd-group><kwd>Atrial fibrillation</kwd><kwd>Surgical ablation</kwd><kwd>Maze</kwd><kwd>Cardiac surgery</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting 1&#x02013;2%
of the general population. It is associated with increased morbidity and
mortality.<sup><xref ref-type="bibr" rid="EHS290C1">1</xref>,<xref ref-type="bibr" rid="EHS290C2">2</xref></sup> Its prevalence increases with age and with the presence of
significant valve or ischaemic heart disease.<sup><xref ref-type="bibr" rid="EHS290C1">1</xref>,<xref ref-type="bibr" rid="EHS290C3">3</xref></sup> The surgical procedure for
the treatment of AF was introduced in 1987 by Dr James L. Cox,<sup><xref ref-type="bibr" rid="EHS290C4">4</xref>,<xref ref-type="bibr" rid="EHS290C5">5</xref></sup> and for more
than two decades, the Cox&#x02013;Maze III procedure represents the standard for AF
treatment.<sup><xref ref-type="bibr" rid="EHS290C6">6</xref></sup></p><p>In recent years, patients undergoing cardiac surgery and suffering from AF are more and
more frequently indicated for some type of concomitant surgical ablation procedure, with
variable lesion sets and energies. However, many surgeons do not routinely treat AF with a
concomitant cardiac surgical procedure. Gammie <italic>et al</italic>.<sup><xref ref-type="bibr" rid="EHS290C7">7</xref></sup> recently reported that in nearly
60% of patients undergoing cardiac surgery, concomitant AF is left untreated. This
may be due to the variety of lesion sets and energy sources, but may also be due to the lack
of clinically convincing results.</p><p>Only a few randomized studies have been published to date and they suffered from relatively
small sample sizes, involving various groupings of patients and with inconsistent published
data relative to mid- and long-term results.<sup><xref ref-type="bibr" rid="EHS290C8">8</xref>&#x02013;<xref ref-type="bibr" rid="EHS290C16">16</xref></sup> These studies
enrolled only patients scheduled for mitral valve surgery&#x02014;thus, the efficacy of
surgical ablation in patients undergoing other types of surgery, e.g. coronary artery bypass
graft (CABG) or aortic valve replacement (AVR), is even less well established, with one
study showing an increased rate of peri-operative complications in the ablation
group.<sup><xref ref-type="bibr" rid="EHS290C12">12</xref></sup> Most studies were able
to demonstrate sinus rhythm (SR) restoration rates, but whether this has any (positive or
negative) impact on major clinical events is not known.</p><p>Thus, a prospective randomized study was designed to estimate the role of surgical ablation
procedures in an unselected group of patients with AF who were candidates for coronary
and/or valve surgery.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Study design and patients</title><p>The PRAGUE-12 trial was a prospective, open, randomized multicentre clinical trial
assessing the outcome of cardiac surgery with left atrial ablation vs. cardiac surgery
alone (without ablation) in patients with coronary and/or valve disease and AF. The
primary hypothesis was that surgical ablation of the left atrium (LA) would result in a
higher incidence of SR in the treated group 1 year after surgery. The primary efficacy
endpoint was SR presence (without any AF episodes) during a 24 h electrocardiogram (ECG)
after 1 year. The primary safety endpoint was a composite of death, myocardial infarction
(MI), stroke, or new onset renal failure (with the need for haemodialysis) at 30 days. The
major secondary endpoint was a composite of death, major bleeding, stroke, or
hospitalization for heart failure within 1 year of surgery. The study design also includes
a 5-year follow-up.</p><p>The trial was approved by the institutional Ethics Committee of each participating centre
and was conducted in accordance with the Declaration of Helsinki. All patients provided a
written informed consent.</p><p>The inclusion criteria were indication for cardiac surgery (CABG, valve replacement or
repair, others, or combinations) and AF (paroxysmal, persistent, or long-standing
persistent) documented at least twice in the previous 6 months before surgery, a signed
informed consent, and an age &#x0003e;18 years. The only exclusion criterion was emergency
surgery. Patients who fulfilled these criteria were randomly assigned to surgery combined
with left atrial ablation (group A) or to surgery without left atrial ablation (group B).
Patient's pre-operative, intra-operative, and early post-operative data were
prospectively recorded. After discharge from the cardiac unit, all follow-up data were
prospectively recorded in anti-arrhythmic units of participating cardiology
departments.</p><p>The study was designed and all data (mainly endpoints definitions) were collected and
presented in accordance with definitions and recommendations for AF-related trials
published by AHA/ACC, STS, EHRA, and AFNET.<sup><xref ref-type="bibr" rid="EHS290C17">17</xref>&#x02013;<xref ref-type="bibr" rid="EHS290C19">19</xref></sup> The types of
AF were defined according to current ESC guidelines.<sup><xref ref-type="bibr" rid="EHS290C1">1</xref></sup></p></sec><sec id="s2b"><title>Surgical procedure</title><p>All patients (groups A and B) underwent a CABG and/or valve surgery through a median
sternotomy, using cardiopulmonary bypass (CPB) and cardioplegic heart arrest. The energy
source for creating lesions was chosen according to the preference of the lead surgeon and
the guidelines of the particular department. In 113 (96.6%) patients, a surgical
cryo-probe with an argon-based cooling system was used (ATS cryomaze 10 cm surgical
ablation probe, ATS Medical, Inc., Minneapolis, MN, USA), and the ablation time for each
lesion was 90 s; in four (3.4%) patients, a radiofrequency was used. The lesion set
was the same for all patients in group A and was performed immediately prior to the valve
or CABG procedure, but after placing the patient on CPB and arresting the heart. It
included pulmonary vein (PV) ablation (left-sided and right-sided PV pairs separately),
left atrial appendage (LAA) surgical resection, and three other
lesions&#x02014;interconnecting lesion between PV pairs, connecting lesion from PV to
mitral annulus, and a lesion from the left upper PV to the rim of the LAA
(<italic>Figure&#x000a0;<xref ref-type="fig" rid="EHS290F1">1</xref></italic>). This
last mentioned lesion was performed endocardially in all patients after the resection of
the LAA. In procedures where the LA was not opened (CABG, aortic/tricuspid valve surgery,
or combination), all other lesions were performed epicardially. In procedures where the LA
was planned to be opened (operations that included mitral valve surgery), all the other
lesions were created endocardially after opening the LA. All procedures were performed
using CO<sub>2</sub> insufflation. Lesion lines were not assessed for conduction block so
as not to prolong the surgical procedure. <fig id="EHS290F1" position="float"><label>Figure&#x000a0;1</label><caption><p>Schematic drawing of the left atrium in a postero-anterior view with the
cryo-ablation lesions (dotted lines) and the left atrial appendage resection. LAA,
left atrial appendage; SVC, superior vena cava; IVC, inferior vena cava; MV, mitral
valve.</p></caption><graphic xlink:href="ehs29001"/></fig></p></sec><sec id="s2c"><title>Treatment strategy</title><p>Patient medication was maintained until the day of surgery except for anticoagulation or
antiplatelet therapy, which was either discontinued 5 days prior to surgery or switched to
heparin. Post-operative care was identical for both groups. Unless contraindicated, all
patients received anti-arrhythmic drugs (AADs) post-operatively on the day of surgery;
amiodarone was the first choice, with propafenone or sotalol as the second choice. All
patients were put on warfarin with a target international normalized ratio of
2&#x02013;2.5. Other medication, including beta-blockers, was adjusted routinely, according
to the patient's comorbidities. It was recommended that AADs be discontinued 3
months after surgery if the patient appears to be AF-free. Unless otherwise
contraindicated, warfarin was recommended to be discontinued 6 months after surgery (i.e.
3 months after discontinuation of AADs) if patients remained in stable SR. Direct current
cardioversion was strongly recommended if AF was present at the 30-day follow-up.
Nevertheless, the actual treatment strategy was left at the discretion of the treating
cardiologists (according to patients' CHADS<sub>2</sub> score and other
characteristics).</p></sec><sec id="s2d"><title>Follow-up</title><p>Cardiac rhythm was continuously monitored until discharge from hospital. Post-operative
follow-ups were scheduled at 1, 3, and 6 months and 1 year after surgery. All of the
follow-ups were performed in the participating cardiology centres. The first three
follow-ups included clinical examination and ECG, the 1-year follow-up also included a 24
h Holter-ECG and ECHO. At each follow-up, data regarding current medications, recent
complications, or hospitalizations were recorded. Since the study was an open design, a
blinded clinical events committee (CEC) was not established; nevertheless, the primary
endpoint analysis was blinded since the Holter-ECGs were performed and analysed by
arrhythmologists who did not have detailed information about the patients.</p></sec><sec id="s2e"><title>Power calculation</title><p>According to available publications, we assumed that the SR restoration rate 1 year after
surgery would be 70% in the ablation group and 30% in the control group. A
power analysis revealed that a minimum of 100 patients per group were required to assure
at least 90% power for detecting the anticipated between-group differences in SR
prevalence at 1-year and 5-year follow-ups and to compensate for the expected drop-out
rate.</p></sec><sec id="s2f"><title>Statistical analysis</title><p>The primary analysis of the study was based on the intention-to-treat principle.
Continuous data are presented as arithmetic means and SD for normally distributed
variables or as medians and the 25th&#x02013;75th percentiles range for log-normally
distributed variables. Normality was tested using the Shapiro&#x02013;Wilk test. Comparison
of groups was based on Student's two-sample <italic>t</italic>-test and the
Mann&#x02013;Whitney test. Within-subjects comparisons at two time points were done using
the paired <italic>t</italic>-test. Categorical data are given as absolute and relative
frequencies (percentages). The differences in proportions between groups were analysed
using Fisher's exact test and its generalization. Analysis of the major secondary
endpoint at one year was based on the log-rank test for interval-censored failure time
data. A logistic regression model was used to identify independent predictors of failure
to restore SR. All statistical tests were treated as two-sided and evaluated at a
significance level of 0.05. Statistical analysis was performed using the statistical
software Stata, release 9.2 (Stata Corp LP, College Station, TX, USA).</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3a"><title>Patients</title><p>A total of 224 patients were enrolled in three university centres between 2007 and 2011.
There were 117 patients randomized into group A and 107 patients into group B. Detailed
patient characteristics are shown in <italic>Table&#x000a0;<xref ref-type="table" rid="EHS290TB1">1</xref></italic>. Both groups were comparable in all baseline
characteristics, except for history of MI and chronic renal disease, which were more
frequent in group B. <table-wrap id="EHS290TB1" position="float"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char=" " span="1"/><col align="char" char=" " span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="left" rowspan="1" colspan="1">Group A (with ablation) (<italic>n</italic> = 117)</th><th align="left" rowspan="1" colspan="1">Group B (without ablation) (<italic>n</italic> = 107)</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">Demography</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Age (years)</td><td rowspan="1" colspan="1">69.9 &#x000b1; 7.8</td><td rowspan="1" colspan="1">71.0 &#x000b1; 7.9</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Female gender, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">50 (42.7)</td><td rowspan="1" colspan="1">44 (41.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Body mass index (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">29.4 &#x000b1; 4.6</td><td rowspan="1" colspan="1">28.8 &#x000b1; 4.4</td></tr><tr><td colspan="3" rowspan="1">AF</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Duration (months)</td><td rowspan="1" colspan="1">15.0 (5.0&#x02013;64.0)</td><td rowspan="1" colspan="1">16.0 (5.0&#x02013;60.0)</td></tr><tr><td colspan="3" rowspan="1">&#x02003;Type of AF, <italic>n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Paroxysmal</td><td rowspan="1" colspan="1">26 (22.2)</td><td rowspan="1" colspan="1">33 (30.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Persistent</td><td rowspan="1" colspan="1">30 (25.6)</td><td rowspan="1" colspan="1">25 (23.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Longstanding persistent</td><td rowspan="1" colspan="1">61 (52.1)</td><td rowspan="1" colspan="1">49 (45.8)</td></tr><tr><td colspan="3" rowspan="1">Pre-operative rhythm, <italic>n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;SR, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">24 (20.5)</td><td rowspan="1" colspan="1">33 (30.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;AF, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">91 (77.8)</td><td rowspan="1" colspan="1">70 (65.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Paced rhythm</td><td rowspan="1" colspan="1">1 (0.9)</td><td rowspan="1" colspan="1">4 (3.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Atrial flutter (typical)</td><td rowspan="1" colspan="1">1 (0.9)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1">Pre-operative cardioversion, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">18 (15.4)</td><td rowspan="1" colspan="1">15 (14.0)</td></tr><tr><td rowspan="1" colspan="1">Pre-operative catheter ablation, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">2 (1.7)</td><td rowspan="1" colspan="1">2 (1.9)</td></tr><tr><td rowspan="1" colspan="1">Left atrial diameter (mm)</td><td rowspan="1" colspan="1">48.7 &#x000b1; 7.3</td><td rowspan="1" colspan="1">47.7 &#x000b1; 7.1</td></tr><tr><td colspan="3" rowspan="1">NYHA functional class, <italic>n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;I</td><td rowspan="1" colspan="1">7 (6.0)</td><td rowspan="1" colspan="1">16 (14.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;II</td><td rowspan="1" colspan="1">66 (56.4)</td><td rowspan="1" colspan="1">51 (47.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;III</td><td rowspan="1" colspan="1">43 (36.7)</td><td rowspan="1" colspan="1">37 (34.6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;IV</td><td rowspan="1" colspan="1">1 (0.9)</td><td rowspan="1" colspan="1">3 (2.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean NYHA functional class</td><td rowspan="1" colspan="1">2.3 &#x000b1; 0.6</td><td rowspan="1" colspan="1">2.3 &#x000b1; 0.7</td></tr><tr><td colspan="3" rowspan="1">Comorbidity, <italic>n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Hypertension</td><td rowspan="1" colspan="1">95 (81.2)</td><td rowspan="1" colspan="1">86 (80.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MI</td><td rowspan="1" colspan="1">23 (19.7)</td><td rowspan="1" colspan="1">37 (34.6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Stroke/TIA</td><td rowspan="1" colspan="1">13 (11.1)</td><td rowspan="1" colspan="1">15 (14.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Diabetes</td><td rowspan="1" colspan="1">41 (35.0)</td><td rowspan="1" colspan="1">40 (37.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Renal failure</td><td rowspan="1" colspan="1">7 (6.0)</td><td rowspan="1" colspan="1">18 (16.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Bleeding</td><td rowspan="1" colspan="1">4 (3.4)</td><td rowspan="1" colspan="1">6 (5.6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Heart failure</td><td rowspan="1" colspan="1">29 (24.8)</td><td rowspan="1" colspan="1">34 (31.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Lung disease</td><td rowspan="1" colspan="1">19 (16.2)</td><td rowspan="1" colspan="1">19 (17.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Thyroid gland disease</td><td rowspan="1" colspan="1">10 (8.5)</td><td rowspan="1" colspan="1">17 (15.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Thrombosis</td><td rowspan="1" colspan="1">5 (4.3)</td><td rowspan="1" colspan="1">7 (6.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;PM/ICD</td><td rowspan="1" colspan="1">9 (7.7)</td><td rowspan="1" colspan="1">15 (14.0)</td></tr><tr><td rowspan="1" colspan="1">Ejection fraction (%)</td><td rowspan="1" colspan="1">52.6 &#x000b1; 10.9</td><td rowspan="1" colspan="1">49.9 &#x000b1; 12.5</td></tr><tr><td rowspan="1" colspan="1">Logistic EuroSCORE</td><td rowspan="1" colspan="1">5.8 (3.2&#x02013;9.9)</td><td rowspan="1" colspan="1">6.8 (4.0&#x02013;11.6)</td></tr><tr><td colspan="3" rowspan="1">Medication, <italic>n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Beta-blocker</td><td rowspan="1" colspan="1">90 (76.9)</td><td rowspan="1" colspan="1">85 (79.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Amiodarone/propafenone</td><td rowspan="1" colspan="1">22 (18.8)</td><td rowspan="1" colspan="1">19 (17.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;ACE-inhibitor</td><td rowspan="1" colspan="1">65 (55.6)</td><td rowspan="1" colspan="1">61 (57.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Digoxin</td><td rowspan="1" colspan="1">30 (25.6)</td><td rowspan="1" colspan="1">24 (22.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Statin</td><td rowspan="1" colspan="1">53 (45.3)</td><td rowspan="1" colspan="1">59 (55.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Sodium warfarin</td><td rowspan="1" colspan="1">81 (69.2)</td><td rowspan="1" colspan="1">69 (64.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Aspirin</td><td rowspan="1" colspan="1">41 (35.0)</td><td rowspan="1" colspan="1">33 (30.8)</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as mean &#x000b1; SD or median, with 25th&#x02013;75th
percentile range in brackets, unless otherwise stated. <italic>n</italic>, number
of patients; AF, atrial fibrillation; NYHA, New York Heart Association; TIA,
transitory ischaemic attack; ICD, implantable cardioverter&#x02013;defibrillator;
EuroSCORE, European System for Cardiac Operative Risk Evaluation; ACE,
angiotensin-converting enzyme; SR, sinus rhythm; MI, myocardial infarction; PM,
pacemaker.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s3b"><title>Peri-operative and post-operative courses</title><p>Two patients from group B were contraindicated to surgery after randomization and those
were excluded from follow-up. Both groups were similar, comparable with regard to types of
operations (<italic>Table&#x000a0;<xref ref-type="table" rid="EHS290TB2">2</xref></italic>). The lesion sets were completely performed in all patients in group A,
and there were no intra-operative complications associated with energy application.
Cross-clamp time, duration of CPB, and the overall surgical time were significantly
prolonged in group A. At the end of surgery, significantly more patients in group A
required epicardial stimulation and more patients in group B concluded the procedure in SR
(<italic>Table&#x000a0;<xref ref-type="table" rid="EHS290TB3">3</xref></italic>).
<table-wrap id="EHS290TB2" position="float"><label>Table&#x000a0;2</label><caption><p>Types of operations</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="left" rowspan="1" colspan="1">Group A (with ablation) (<italic>n</italic> = 117)</th><th align="left" rowspan="1" colspan="1">Group B (without ablation) (<italic>n</italic> = 105)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Without mitral surgery, <italic>n</italic></td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">60</td></tr><tr><td rowspan="1" colspan="1">&#x02003;CABG</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">31</td></tr><tr><td rowspan="1" colspan="1">&#x02003;AVR</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">13</td></tr><tr><td rowspan="1" colspan="1">&#x02003;TVP</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;AVR + CABG</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">11</td></tr><tr><td rowspan="1" colspan="1">&#x02003;AVR + TVP</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">&#x02003;TVP + CABG</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;AVR + TVP + CABG</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">With mitral surgery, <italic>n</italic></td><td rowspan="1" colspan="1">58</td><td rowspan="1" colspan="1">45</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MVP</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MVR</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MVP + CABG</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MVR + CABG</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;AVR + MVP</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">&#x02003;AVR + MVR</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MVP + TVP</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">13</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MVR + TVP</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">&#x02003;AVR + MVP + CABG</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;AVR + MVR + CABG</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MVP + TVP + CABG</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">9</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MVR + TVP + CABG</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;AVR + MVP + TVP</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">&#x02003;AVR + MVR + TVP</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">&#x02003;AVR + MVP + TVP + CABG</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn><p><italic>n</italic>, number of patients; CABG, coronary artery bypass graft;
AVR, aortic valve replacement; MVP, mitral valve plasty; MVR, mitral valve
replacement; TVP, tricuspid valve plasty.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="EHS290TB3" position="float"><label>Table&#x000a0;3</label><caption><p>Operative characteristics</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="left" rowspan="1" colspan="1">Group A (with ablation) (<italic>n</italic> = 117)</th><th align="left" rowspan="1" colspan="1">Group B (without ablation) (<italic>n</italic> = 105)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Duration of surgery (min)</td><td rowspan="1" colspan="1">220 (180&#x02013;255)</td><td rowspan="1" colspan="1">200 (165&#x02013;240)</td><td rowspan="1" colspan="1">0.003</td></tr><tr><td rowspan="1" colspan="1">CPB (min)</td><td rowspan="1" colspan="1">100 (74&#x02013;121)</td><td rowspan="1" colspan="1">72 (46&#x02013;97)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Cross-clamp time (min)</td><td rowspan="1" colspan="1">78 (46&#x02013;96)</td><td rowspan="1" colspan="1">51 (31.5&#x02013;73)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="4" rowspan="1">End-operation rhythm, <italic>n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;SR</td><td rowspan="1" colspan="1">69 (59.0%)</td><td rowspan="1" colspan="1">79 (75.2%)</td><td rowspan="1" colspan="1">&#x0003c;0.001<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">&#x02003;AF</td><td rowspan="1" colspan="1">12 (10.3%)</td><td rowspan="1" colspan="1">16 (15.2%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Epicardial stimulation</td><td rowspan="1" colspan="1">36 (30.8%)</td><td rowspan="1" colspan="1">10 (9.5%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Blood loss (mL)</td><td rowspan="1" colspan="1">680 (450&#x02013;1115)</td><td rowspan="1" colspan="1">705 (445&#x02013;945)</td><td rowspan="1" colspan="1">0.565</td></tr><tr><td rowspan="1" colspan="1">Hospital stay (days)</td><td rowspan="1" colspan="1">8 (7&#x02013;12)</td><td rowspan="1" colspan="1">8 (6&#x02013;11)</td><td rowspan="1" colspan="1">0.307</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as median, with 25th&#x02013;75th percentile range in
brackets unless otherwise stated. <italic>n</italic>, number of patients; CPB,
cardiopulmonary bypass; SR, sinus rhythm; AF, atrial fibrillation.</p></fn><fn><p><sup>a</sup>Fisher's exact test or generalized Fisher's exact
test was used.</p></fn></table-wrap-foot></table-wrap></p><p>Eleven in-hospital deaths occurred, six (5.1%) in group A and five (4.7%)
in group B. Five patients died because of multi-organ failure, four because of cardiogenic
shock or refractory heart failure, one died of ischaemia, and one died of sepsis. Other
post-operative complications (except for those included in the primary safety endpoint)
are shown in <italic>Table&#x000a0;<xref ref-type="table" rid="EHS290TB4">4</xref></italic>. Seven patients from group A and one from group B required an
in-hospital pacemaker (PM) and/or implantable cardioverter&#x02013;defibrillator (ICD)
implantation to treat second or third degree AV block. The length of hospital stay was
comparable in both groups. <table-wrap id="EHS290TB4" position="float"><label>Table&#x000a0;4</label><caption><p>Other 30 days' complications</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Complications</th><th align="left" rowspan="1" colspan="1">Group A (with ablation) (<italic>n</italic> = 116)</th><th align="left" rowspan="1" colspan="1">Group B (without ablation) (<italic>n</italic> = 102)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Operative revision for bleeding</td><td rowspan="1" colspan="1">10 (8.6%)</td><td rowspan="1" colspan="1">9 (8.8%)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Other bleeding complication</td><td rowspan="1" colspan="1">5 (4.3%)</td><td rowspan="1" colspan="1">6 (5.9%)</td><td rowspan="1" colspan="1">0.759</td></tr><tr><td rowspan="1" colspan="1">Pneumothorax</td><td rowspan="1" colspan="1">4 (3.4%)</td><td rowspan="1" colspan="1">3 (2.9%)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Pleural effusion with puncture</td><td rowspan="1" colspan="1">16 (13.8%)</td><td rowspan="1" colspan="1">16 (15.7%)</td><td rowspan="1" colspan="1">0.706</td></tr><tr><td rowspan="1" colspan="1">Pneumonia</td><td rowspan="1" colspan="1">3 (2.6%)</td><td rowspan="1" colspan="1">4 (3.9%)</td><td rowspan="1" colspan="1">0.708</td></tr><tr><td rowspan="1" colspan="1">Respiratory insufficiency with re-intubation</td><td rowspan="1" colspan="1">3 (2.6%)</td><td rowspan="1" colspan="1">8 (7.8%)</td><td rowspan="1" colspan="1">0.119</td></tr><tr><td rowspan="1" colspan="1">Sternal wound infection</td><td rowspan="1" colspan="1">2 (1.7%)</td><td rowspan="1" colspan="1">0 (0.0%)</td><td rowspan="1" colspan="1">0.500</td></tr><tr><td rowspan="1" colspan="1">Heart failure with rehospitalization</td><td rowspan="1" colspan="1">14 (12.1%)</td><td rowspan="1" colspan="1">14 (13.7%)</td><td rowspan="1" colspan="1">0.840</td></tr><tr><td rowspan="1" colspan="1">Multi-organ failure</td><td rowspan="1" colspan="1">5 (4.3%)</td><td rowspan="1" colspan="1">4 (3.9%)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">PM implantation</td><td rowspan="1" colspan="1">7 (6.0%)</td><td rowspan="1" colspan="1">1 (1.0%)</td><td rowspan="1" colspan="1">0.070</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as number with percentage in brackets. Fisher's exact
test was used. <italic>n</italic>, number of patients; PM, pacemaker.</p></fn></table-wrap-foot></table-wrap></p><p>At each follow-up, we analysed data from all patients who reached a given scheduled
follow-up point (i.e. 1, 3, 6 months, and 1 year). The exact number of ECGs analysed is
shown in <italic>Figure&#x000a0;<xref ref-type="fig" rid="EHS290F2">2</xref></italic>. The
overall retention relative to clinical follow-ups is shown in the legend of
<italic>Figure&#x000a0;<xref ref-type="fig" rid="EHS290F2">2</xref></italic>. At the
time of data analysis, the last 13 patients enrolled had not yet reached the 1-year
follow-up, which affected the overall retention for the 1-year follow-up. A total of 169
patients were included in the primary endpoint analysis 1 year after surgery (93
Holter-ECGs were recorded and analysed in group A and 76 in group B). <fig id="EHS290F2" position="float"><label>Figure&#x000a0;2</label><caption><p>Electrocardiogram-verified sinus rhythm prevalence graph. The numbers below
each column represent the number of electrocardiograms analysed/the number of
electrocardiograms with sinus rhythm. Overall completeness of clinical follow-up
(patients who died were included) was 97.8% at 1 month, 94.6% at 3
months, 95.1% at 6 months, and 91.4% at 1 year.</p></caption><graphic xlink:href="ehs29002"/></fig></p><p>Comparing baseline characteristics of patients who were not included in the primary
endpoint analysis (Not-analysed, i.e. died, refused follow-ups, or have not reached the
1-year endpoint yet) with those who were included (Analysed) showed a significantly higher
prevalence of the use of angiotensin-converting enzyme-inhibitors (69.8 vs. 51.5%,
<italic>P</italic> = 0.026), renal disease (20.8 vs. 8.3%,
<italic>P</italic> = 0.022), lung disease (30.2 vs. 13.4%,
<italic>P</italic> = 0.005), and hypertension (90.6 vs. 78.1%,
<italic>P</italic> = 0.046) in the Not-analysed group. Those patients also had a
shorter hospital stay (median of 7 vs. 8 days for the Analysed group, <italic>P</italic>
= 0.011).</p></sec><sec id="s3c"><title>Primary outcomes</title><p>In group A, 56 of 93 patients (60.2%) showed SR (without any AF episodes) on the
24 h Holter-ECG 1 year after surgery, compared with 27 patients of 76 (35.5%) in
group B (<italic>P</italic> = 0.002). The primary combined safety endpoint at 30
days after surgery did not show any significant difference in any of the followed
(serious) post-operative complications (<italic>Table&#x000a0;<xref ref-type="table" rid="EHS290TB5">5</xref></italic>). <table-wrap id="EHS290TB5" position="float"><label>Table&#x000a0;5</label><caption><p>Primary safety endpoint (30 days)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Complications</th><th align="left" rowspan="1" colspan="1">Group A (with ablation) (<italic>n</italic> = 116)</th><th align="left" rowspan="1" colspan="1">Group B (without ablation) (<italic>n</italic> = 102)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Primary combined safety endpoint</td><td rowspan="1" colspan="1">12 (10.3%)</td><td rowspan="1" colspan="1">15 (14.7%)</td><td rowspan="1" colspan="1">0.411</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Death</td><td rowspan="1" colspan="1">9 (7.8%)</td><td rowspan="1" colspan="1">9 (8.8%)&#x000a0;</td><td rowspan="1" colspan="1">0.809</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Myocardial ischaemia</td><td rowspan="1" colspan="1">2 (1.7%)</td><td rowspan="1" colspan="1">2 (2.0%)</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Stroke</td><td rowspan="1" colspan="1">2 (1.7%)</td><td rowspan="1" colspan="1">4 (3.9%)</td><td rowspan="1" colspan="1">0.422</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Renal failure with HD</td><td rowspan="1" colspan="1">1 (0.9%)</td><td rowspan="1" colspan="1">4 (3.9%)</td><td rowspan="1" colspan="1">0.188</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as number with percentage in brackets. Fisher's exact
test was used. HD, haemodialysis.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s3d"><title>Other outcomes (1-year follow-up)</title><p>The occurrence of serious complications at the 1-year follow-up was similar in both
groups (<italic>Table&#x000a0;<xref ref-type="table" rid="EHS290TB6">6</xref></italic>).
The SR prevalence verified by ECGs at each time point is shown in detail in
<italic>Figure&#x000a0;<xref ref-type="fig" rid="EHS290F2">2</xref></italic>.
<table-wrap id="EHS290TB6" position="float"><label>Table&#x000a0;6</label><caption><p>One-year complications</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Complications</th><th align="left" rowspan="1" colspan="1">Group A (with ablation) (<italic>n</italic> = 111)</th><th align="left" rowspan="1" colspan="1">Group B (without ablation) (<italic>n</italic> = 92)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Death</td><td rowspan="1" colspan="1">18 (16.2%)</td><td rowspan="1" colspan="1">16 (17.4%)</td><td rowspan="1" colspan="1">0.800</td></tr><tr><td rowspan="1" colspan="1">Bleeding</td><td rowspan="1" colspan="1">11 (9.9%)</td><td rowspan="1" colspan="1">9 (9.8%)</td><td rowspan="1" colspan="1">0.654</td></tr><tr><td rowspan="1" colspan="1">Stroke</td><td rowspan="1" colspan="1">3 (2.7%)</td><td rowspan="1" colspan="1">4 (4.3%)</td><td rowspan="1" colspan="1">0.319</td></tr><tr><td rowspan="1" colspan="1">Heart failure</td><td rowspan="1" colspan="1">26 (23.4%)</td><td rowspan="1" colspan="1">24 (26.1%)</td><td rowspan="1" colspan="1">0.680</td></tr><tr><td rowspan="1" colspan="1">Combined</td><td rowspan="1" colspan="1">45 (40.5%)</td><td rowspan="1" colspan="1">37 (40.2%)</td><td rowspan="1" colspan="1">0.785</td></tr></tbody></table><table-wrap-foot><fn><p>Fisher's exact test was used. The groups were compared using the
log-rank test for interval-censored data. <italic>n</italic>, number of
patients.</p></fn></table-wrap-foot></table-wrap></p><p>Of the patients in SR 1 year after surgery, 36 (64.2%) in group A were without
AADs and 23 (41%) were without warfarin compared with 20 (74%) and 11
(40.7%) in group B, respectively. However, of the remaining 33 anticoagulated
patients in group A, 14 received a mechanical valve and 2 had other indications for
chronic anticoagulation. Details regarding anti-arrhythmic therapy during follow-up are
presented in <italic>Table&#x000a0;<xref ref-type="table" rid="EHS290TB7">7</xref></italic>. <table-wrap id="EHS290TB7" position="float"><label>Table&#x000a0;7</label><caption><p>Anti-arrhythmic therapy during follow-up</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char=" " span="1"/><col align="char" char=" " span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Medication</th><th align="left" rowspan="1" colspan="1">Group A (with ablation)</th><th align="left" rowspan="1" colspan="1">Group B (without ablation)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Discharge, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"><italic>n</italic> = 111</td><td rowspan="1" colspan="1"><italic>n</italic> = 100</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Beta-blockers</td><td rowspan="1" colspan="1">64 (58%)</td><td rowspan="1" colspan="1">67 (67%)</td><td rowspan="1" colspan="1">0.162</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Anti-arrhythmics</td><td rowspan="1" colspan="1">91 (82%)</td><td rowspan="1" colspan="1">76 (76%)</td><td rowspan="1" colspan="1">0.285</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Digitalis</td><td rowspan="1" colspan="1">9 (8%)</td><td rowspan="1" colspan="1">7 (7%)</td><td rowspan="1" colspan="1">0.761</td></tr><tr><td rowspan="1" colspan="1">Day 30, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"><italic>n</italic> = 107</td><td rowspan="1" colspan="1"><italic>n</italic> = 93</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Beta-blockers</td><td rowspan="1" colspan="1">74 (69%)</td><td rowspan="1" colspan="1">69 (74%)</td><td rowspan="1" colspan="1">0.431</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Anti-arrhythmics</td><td rowspan="1" colspan="1">80 (75%)</td><td rowspan="1" colspan="1">62 (67%)</td><td rowspan="1" colspan="1">0.207</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Digitalis</td><td rowspan="1" colspan="1">10 (9%)</td><td rowspan="1" colspan="1">6 (7%)</td><td rowspan="1" colspan="1">0.451</td></tr><tr><td rowspan="1" colspan="1">Year 1, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"><italic>n</italic> = 93</td><td rowspan="1" colspan="1"><italic>n</italic> = 76</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Beta-blockers</td><td rowspan="1" colspan="1">67 (72%)</td><td rowspan="1" colspan="1">59 (78%)</td><td rowspan="1" colspan="1">0.406</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Anti-arrhythmics</td><td rowspan="1" colspan="1">29 (31%)</td><td rowspan="1" colspan="1">17 (22%)</td><td rowspan="1" colspan="1">0.200</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Digitalis</td><td rowspan="1" colspan="1">10 (11%)</td><td rowspan="1" colspan="1">12 (16%)</td><td rowspan="1" colspan="1">0.333</td></tr></tbody></table><table-wrap-foot><fn><p>Anti-arrhythmics: amiodarone, sotalol, or propafenone. Fisher's exact
test was used. <italic>n</italic>, number of patients.</p></fn></table-wrap-foot></table-wrap></p><p>Except for the early PM implantations mentioned above, another 4 patients in group A and
11 in group B required PM implantation between day 30 and the 1-year follow-up. Overall,
the number of PM implantations in the first post-operative year was 11 (9.9%) in
group A and 12 (13%) in group B, (<italic>P</italic> = 0.512).</p><p>There was no significant change in mean left ventricular ejection fraction; in group A,
it increased by 0.7 &#x000b1; 9.1 vs. 1.1 &#x000b1; 11.3% in group B
(<italic>P</italic> = 0.825). The mean LA diameter enlarged non-significantly by
1.3 &#x000b1; 7.3 mm in group A (<italic>P</italic> = 0.085) and significantly by
1.5 &#x000b1; 6.0 mm in group B (<italic>P</italic> = 0.037); however, comparisons
of means differences were non-significant (<italic>P</italic> = 0.887). In patients
with successfully restored SR 1 year after surgery, the mean LA size increased by 0.5
&#x000b1; 7.4 mm compared with 2.2 &#x000b1; 5.8 mm in patients who remained in AF
(<italic>P</italic> = 0.112). Patients in both groups (A and B) exhibited a
similar improvement in the New York Heart Association functional class; the mean decrease
was 0.76 &#x000b1; 0.9 in group A vs. 0.58 &#x000b1; 0.85 in group B (<italic>P</italic>
= 0.174).</p><p>Analysis of SR prevalence 1 year after surgery according to the type of pre-operative AF
revealed that SR presence was much more common in group A compared with group B for all AF
types. The difference (A vs. B) was significant in patients with pre-operative
long-standing persistent AF (53.2 vs. 13.9%, <italic>P</italic> &#x0003c; 0.001). In
intermittent pre-operative types of AF, the difference was non-significant (61.9 vs.
58.3%, <italic>P</italic> = 1.000 in paroxysmal; 72 vs. 50%,
<italic>P</italic> = 0.194 in persistent AF). The overall group-by-AF type
interaction <italic>P</italic>-value was 0.093. Detailed information regarding SR
prevalence 1 year after surgery, relative to the type of surgery, is presented in
<italic>Table&#x000a0;<xref ref-type="table" rid="EHS290TB8">8</xref></italic>. The
overall group-by-mitral surgery interaction <italic>P</italic>-value was 0.725.
<table-wrap id="EHS290TB8" position="float"><label>Table&#x000a0;8</label><caption><p>Sinus rhythm prevalence at 1 year according to the type of
surgery</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Complications</th><th align="left" rowspan="1" colspan="1">Group A (with ablation) (<italic>n</italic> = 93)</th><th align="left" rowspan="1" colspan="1">Group B (without ablation) (<italic>n</italic> = 76)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td colspan="4" rowspan="1">Without MS</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Overall</td><td rowspan="1" colspan="1">27/46 (58.7%)</td><td rowspan="1" colspan="1">15/41 (36.6%)</td><td rowspan="1" colspan="1">0.053</td></tr><tr><td rowspan="1" colspan="1">&#x02003;CABG alone</td><td rowspan="1" colspan="1">9/18 (50%)</td><td rowspan="1" colspan="1">7/21 (33.3%)</td><td rowspan="1" colspan="1">0.342</td></tr><tr><td rowspan="1" colspan="1">&#x02003;AVR alone</td><td rowspan="1" colspan="1">8/14 (57.1%)</td><td rowspan="1" colspan="1">5/11 (45.5%)</td><td rowspan="1" colspan="1">0.695</td></tr><tr><td colspan="4" rowspan="1">With MS</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Overall</td><td rowspan="1" colspan="1">29/47 (61.7%)</td><td rowspan="1" colspan="1">12/35 (34.3%)</td><td rowspan="1" colspan="1">0.025</td></tr><tr><td rowspan="1" colspan="1">&#x02003;With CABG</td><td rowspan="1" colspan="1">10/13 (76.9%)</td><td rowspan="1" colspan="1">7/13 (53.9%)</td><td rowspan="1" colspan="1">0.411</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Without CABG</td><td rowspan="1" colspan="1">19/34 (55.9%)</td><td rowspan="1" colspan="1">5/22 (22.7%)</td><td rowspan="1" colspan="1">0.026</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as number of patients in sinus rhythm/total number of
patients (with percentage in brackets). Fisher's exact test was used.
<italic>n</italic>, number of patients; MS, mitral surgery; CABG, coronary
artery bypass graft; AVR, aortic valve replacement.</p></fn></table-wrap-foot></table-wrap></p><p>Multiple logistic regression analysis identified a longer pre-operative AF history as the
only significant independent risk factor (<italic>P</italic> = 0.024). An
association between failure and the degree of dilatation seen in the LA was different
between groups A and B (<italic>P</italic> = 0.039) and was more pronounced in
group B only (<italic>P</italic> = 0.047).</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>The original Cox-Maze III operation had a 95% success rate in restoring SR that
persisted 5 years after surgery.<sup><xref ref-type="bibr" rid="EHS290C20">20</xref>,<xref ref-type="bibr" rid="EHS290C21">21</xref></sup> Its significant effect on the reduction
in the rate of cerebrovascular accidents and transient ischaemic events has also been
described.<sup><xref ref-type="bibr" rid="EHS290C22">22</xref>,<xref ref-type="bibr" rid="EHS290C23">23</xref></sup> However, this method has not expanded a lot, mainly
because it is a technically difficult and demanding procedure. A systematic review published
in 2005 by Khargi <italic>et al</italic>.<sup><xref ref-type="bibr" rid="EHS290C24">24</xref></sup> reports comparable efficacy rates for the cut-and-sew Maze III surgery
and ablation procedures using alternative energy sources; however, the limitation of that
review was that rhythms were evaluated at a fairly short time of 6 months following
procedure.</p><p>In the 2008 edition of <italic>Cardiac Surgery in the Adult</italic>, Voeller <italic>et
al</italic>.<sup><xref ref-type="bibr" rid="EHS290C25">25</xref></sup> strongly recommend
a concomitant Cox-Maze procedure to all patients with AF who were scheduled to undergo
elective cardiac surgery.<sup><xref ref-type="bibr" rid="EHS290C25">25</xref></sup> Despite
all the facts, a large data registry study shows that &#x0003c;50% patients receive
some type of concomitant AF ablation when undergoing cardiac surgery.<sup><xref ref-type="bibr" rid="EHS290C7">7</xref></sup> We believe that this fact is strongly
related to the lack of convincing results based on randomized studies with long-term
follow-ups.</p><p>The aim of our trial was to assess the long-term efficacy and safety of surgical ablation
compared with pharmacological treatment in non-selected, typical, realistic population of
patients undergoing CABG and/or valve surgery. Cryo-energy (in most cases) and the left
atrial lesion set were used, as they represented the standard ablation procedure used in the
participating centres.</p><p>Our results show a significant improvement in restoring SR in the ablation group relative
to the control group (60% in group A vs. 35.5% in group B, <italic>P</italic>
= 0.002). Camm <italic>et al</italic>.<sup><xref ref-type="bibr" rid="EHS290C26">26</xref></sup> published a review of the nine most relevant papers, which reported
efficacy of cryo-ablation in concomitant cardiac surgery. They found the SR prevalence at 1
year to be between 60 and 82%, which is very similar to our ablation group results.
Similar comparisons can be made with trials that describe the efficacy of LA ablation
procedures to be between 58 and 95%.<sup><xref ref-type="bibr" rid="EHS290C25">25</xref></sup></p><p>A significant distinction was found when we analysed the SR prevalence at 1 year relative
to the type of pre-operative AF. Many studies reported better results for ablation in
patients with intermittent forms of AF compared with the continuous form.<sup><xref ref-type="bibr" rid="EHS290C26">26</xref></sup> Gammie <italic>et al</italic>.<sup><xref ref-type="bibr" rid="EHS290C27">27</xref></sup> reported an SR prevalence of 85%
in intermittent AF and 47% in continuous AF 3 years after cryo-ablation. In our
trial, the SR prevalence was found in 61.9% of those with paroxysmal, 72% of
those with persistent, and in 53.2% of those with long-standing persistent AF, but
compared with SR prevalence in the control group (B), a significant difference was found
only in long-standing persistent AF (<italic>P</italic> &#x0003c; 0.001). Our explanation is
that in intermittent forms of AF, the efficacy in both groups (but probably more in the
group without ablation) was partly received due to ECG-unrecognized episodes of AF, that
camouflage the real effect in the ablation group. Therefore, with one 24 h Holter recording,
the real effect of the ablation procedure is more objectively shown in patients with
long-standing persistent AF and that is why a significant difference could be obtained in
this group even with a single ECG-Holter after 1 year. Additionally, our results show an
overall difference in SR prevalence in both groups when we compared results based on ECGs
(shown in <italic>Figure&#x000a0;<xref ref-type="fig" rid="EHS290F2">2</xref></italic>) with
Holter-ECGs (primary endpoint). Therefore, the efficacy of usage of single ECG-Holter
monitoring seems to be arguable for correct evaluation of efficacy of heart rhythm after
ablation procedures, whereas the total deficiency of monitoring using only an ECG has
already been demonstrated.<sup><xref ref-type="bibr" rid="EHS290C28">28</xref></sup> In our
study, we preferred this &#x02018;patient-friendly&#x02019; monitoring strategy, because we
felt that it gave us better compliance compared with Holter-ECGs that were scheduled more
frequently.</p><p>Another interesting feature was noted when we analysed patients according to the type of
concomitant surgery. In patients in whom the mitral valve was not involved, the overall
difference of SR prevalence in group A compared with B was very close to the level of
significance (<italic>P</italic> = 0.053), but was non-significant in patients who
underwent CABG alone (<italic>P</italic> = 0.342) or AVR alone (<italic>P</italic>
= 0.695). In patients in whom the mitral valve was involved, the effect was
significant (<italic>P</italic> = 0.025), but when we divided those patients based on
coronary artery disease (CAD), significance was found only in patients without CAD
(<italic>P</italic> = 0.026). This might support a finding by the authors of the
SWEDMAF trial,<sup><xref ref-type="bibr" rid="EHS290C12">12</xref></sup> who speculated that
CAD could be a risk factor for failed cryo-ablation. It is worth mentioning that both
divisions were found to be without a statistically significant relationship
(<italic>P</italic> = 0.249).</p><p>Our peri-operative results were in agreement with the fact that the addition of surgical
ablation was not associated with increased operative risk.<sup><xref ref-type="bibr" rid="EHS290C29">29</xref></sup> Blood loss and duration of hospital stay were
equivalent. Occurrence of early serious post-operative complications did not differ in any
of the conditions that we monitored, including death, MI, stroke, or renal failure with a
need for haemodialysis. There were more patients who needed a PM implantation in group
A&#x02014;the difference was close to a level of significance (<italic>P</italic> =
0.070), but did not reach it although significance was reached in other
publications.<sup><xref ref-type="bibr" rid="EHS290C7">7</xref>,<xref ref-type="bibr" rid="EHS290C28">28</xref></sup></p><p>An important aim of our study was to assess the long-term effects of ablation. Our 1 year
results did not show any significant clinical benefit for patients who received concomitant
AF ablation. Overall 1-year mortality was 16.2% in group A and 17.4% in group
B (<italic>P</italic> = 0.800). Occurrences of serious complications were similar in
both groups, including major bleeding events, incidence of stroke, and hospitalization for
signs of heart failure. This combined endpoint was positive in 40.5% of patients in
group A and 40.2% in group B (<italic>P</italic> = 0.785). Even though the
effect of ablation on the decreased incidence of strokes or stroke-related deaths are often
reported,<sup><xref ref-type="bibr" rid="EHS290C23">23</xref>,<xref ref-type="bibr" rid="EHS290C30">30</xref></sup> we found remarkable, but non-significant, differences in
stroke rates in favour of the ablation group at both the 30-day and 1-year follow-ups.</p><p>More significant ablation effects, relative to mortality and morbidity, are expected in the
long term<sup><xref ref-type="bibr" rid="EHS290C31">31</xref></sup>; therefore, a 5-year
follow-up is planned. Analysis of left atrial cryo-ablation failure risk factors found age,
size of the LA, and pre-operative duration of AF to be risk factors of failure-to-restore SR
in the whole set of patients; this was in accordance with other publications.<sup><xref ref-type="bibr" rid="EHS290C32">32</xref>&#x02013;<xref ref-type="bibr" rid="EHS290C34">34</xref></sup></p><sec id="s4a"><title>Limitations of the study</title><p>This study has several limitations. First, the rhythm monitoring by ECGs and by single 24
h Holter-ECG may fail to detect certain recurrences of AF. This is an inherent limitation
in all AF studies without implantable devices. Therefore, the actual SR prevalence could
be overestimated, especially in patients with pre-operative paroxysmal or persistent AF;
nevertheless, this mistake would most likely be equally distributed in both groups.
Second, follow-ups were not completed in all patients. In addition to the expected
drop-outs, the last 13 patients to enter the study had not reached the 1-year follow-up
when the data were analysed, which partially skewed the retention rates for the 1-year
follow-up. Third, differences (described in the Results section) were found between
patients who were analysed for the primary endpoint and patients who were not analysed for
the primary endpoint; however, in our opinion, those differences show mainly the corollary
between higher pre-operative morbidity and post-operative mortality in the Not-analysed
group. Fourth, as our study was focused mainly on the clinical impact of ablation, some
other issues that are useful to follow (mainly data on atrial function) were not part of
our focus. Fifth, since a blinded CEC was not established, the events were not evaluated
in a blinded manner. Sixth, as the expected impact of ablation was not seen during the
first year following surgery, a longer follow-up period seems to be necessary. We plan a
5-year follow-up with the possibility of a 1-week Holter-ECG as the final follow-up
evaluation.</p><p>In conclusion, this prospective randomized study showed that adding left atrial
cryo-ablation of AF to a cardiac surgery is safe and increases the SR prevalence at 1 year
after surgery, although a benefit in peri-operative and 1-year mortality or morbidity was
not found.</p></sec></sec><sec id="s5"><title>Funding</title><p>The study was partially funded, including the Open Access publication charges for this
article, by the <funding-source>Charles University Research</funding-source> projects
<award-id>MSM0021620817</award-id> and <funding-source>UNCE</funding-source>
<award-id>204010/2012</award-id>.</p><p><bold>Conflict of interest:</bold> none declared.</p></sec></body><back><fn-group><fn><p>
<bold>See page 2636 for the editorial comment on this article
(doi:10.1093/eurheartj/ehs294)</bold>
</p></fn></fn-group><ref-list><title>References</title><ref id="EHS290C1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camm</surname><given-names>AJ</given-names></name><name><surname>Kirchhof</surname><given-names>P</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name><name><surname>Schotten</surname><given-names>U</given-names></name><name><surname>Savelieva</surname><given-names>I</given-names></name><name><surname>Ernst</surname><given-names>S</given-names></name><name><surname>Van Gelder</surname><given-names>IC</given-names></name><name><surname>Al-Attar</surname><given-names>N</given-names></name><name><surname>Hindricks</surname><given-names>G</given-names></name><name><surname>Prendergast</surname><given-names>B</given-names></name><name><surname>Heidbuchel</surname><given-names>H</given-names></name><name><surname>Alfieri</surname><given-names>O</given-names></name><name><surname>Angelini</surname><given-names>A</given-names></name><name><surname>Atar</surname><given-names>D</given-names></name><name><surname>Colonna</surname><given-names>P</given-names></name><name><surname>De Caterina</surname><given-names>R</given-names></name><name><surname>De Sutter</surname><given-names>J</given-names></name><name><surname>Goette</surname><given-names>A</given-names></name><name><surname>Gorenek</surname><given-names>B</given-names></name><name><surname>Heldal</surname><given-names>M</given-names></name><name><surname>Hohloser</surname><given-names>SH</given-names></name><name><surname>Kolh</surname><given-names>P</given-names></name><name><surname>Le Heuzey</surname><given-names>JY</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name><name><surname>Rutten</surname><given-names>FH</given-names></name></person-group><collab>European Heart Rhythm Association, European Association for Cardio-Thoracic
Surgery</collab><article-title>Guidelines for the management of atrial fibrillation: the Task Force for
the Management of Atrial Fibrillation of the European Society of Cardiology
(ESC)</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><fpage>2369</fpage><lpage>2429</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/eurheartj/ehq278">doi:10.1093/eurheartj/ehq278</ext-link></comment><pub-id pub-id-type="pmid">20802247</pub-id></element-citation></ref><ref id="EHS290C2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chugh</surname><given-names>S</given-names></name><name><surname>Blackshear</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Hammill</surname><given-names>S</given-names></name><name><surname>Gersh</surname><given-names>B</given-names></name></person-group><article-title>Epidemiology and natural history of atrial fibrillation: clinical
implications</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>37</volume><fpage>371</fpage><lpage>378</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0735-1097(00)01107-4">doi:10.1016/S0735-1097(00)01107-4</ext-link></comment><pub-id pub-id-type="pmid">11216949</pub-id></element-citation></ref><ref id="EHS290C3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krahn</surname><given-names>A</given-names></name><name><surname>Manfreda</surname><given-names>J</given-names></name><name><surname>Tate</surname><given-names>R</given-names></name><name><surname>Mathewson</surname><given-names>FA</given-names></name><name><surname>Cuddy</surname><given-names>TE</given-names></name></person-group><article-title>The natural history of atrial fibrillation: incidence, risk factors, and
prognosis in the Manitoba Follow-Up Study</article-title><source>Am J Med</source><year>1995</year><volume>98</volume><fpage>476</fpage><lpage>484</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0002-9343(99)80348-9">doi:10.1016/S0002-9343(99)80348-9</ext-link></comment><pub-id pub-id-type="pmid">7733127</pub-id></element-citation></ref><ref id="EHS290C4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>JL</given-names></name><name><surname>Schuessler</surname><given-names>RB</given-names></name><name><surname>D'Agostino</surname><given-names>HJ</given-names><suffix>Jr</suffix></name><name><surname>Stone</surname><given-names>CM</given-names></name><name><surname>Chang</surname><given-names>BC</given-names></name><name><surname>Cain</surname><given-names>ME</given-names></name><name><surname>Corr</surname><given-names>PB</given-names></name><name><surname>Boineau</surname><given-names>JP</given-names></name></person-group><article-title>The surgical treatment of atrial fibrillation. III. Development of a
definitive surgical procedure</article-title><source>J Thorac Cardiovasc Surg</source><year>1991</year><volume>101</volume><fpage>569</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">2008095</pub-id></element-citation></ref><ref id="EHS290C5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>JL</given-names></name></person-group><article-title>The first Maze procedure</article-title><source>J Thorac Cardiovasc Surg</source><year>2011</year><volume>141</volume><fpage>1093</fpage><lpage>1097</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jtcvs.2010.12.012">doi:10.1016/j.jtcvs.2010.12.012</ext-link></comment><pub-id pub-id-type="pmid">21497230</pub-id></element-citation></ref><ref id="EHS290C6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calkins</surname><given-names>H</given-names></name><name><surname>Brugada</surname><given-names>J</given-names></name><name><surname>Packer</surname><given-names>DL</given-names></name><name><surname>Cappato</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>SA</given-names></name><name><surname>Crijns</surname><given-names>HJ</given-names></name><name><surname>Damiano</surname><given-names>RJ</given-names><suffix>Jr</suffix></name><name><surname>Davies</surname><given-names>DW</given-names></name><name><surname>Haines</surname><given-names>DE</given-names></name><name><surname>Haissaguerre</surname><given-names>M</given-names></name><name><surname>Iesaka</surname><given-names>Y</given-names></name><name><surname>Jackman</surname><given-names>W</given-names></name><name><surname>Jais</surname><given-names>P</given-names></name><name><surname>Kottkamp</surname><given-names>H</given-names></name><name><surname>Kuck</surname><given-names>KH</given-names></name><name><surname>Lindsay</surname><given-names>BD</given-names></name><name><surname>Marchlinski</surname><given-names>FE</given-names></name><name><surname>McCarthy</surname><given-names>PM</given-names></name><name><surname>Mont</surname><given-names>JL</given-names></name><name><surname>Morady</surname><given-names>F</given-names></name><name><surname>Nademanee</surname><given-names>K</given-names></name><name><surname>Natale</surname><given-names>A</given-names></name><name><surname>Pappone</surname><given-names>C</given-names></name><name><surname>Prystowsky</surname><given-names>E</given-names></name><name><surname>Raviele</surname><given-names>A</given-names></name><name><surname>Ruskin</surname><given-names>JN</given-names></name><name><surname>Shemin</surname><given-names>RJ</given-names></name></person-group><collab>European Heart Rhythm Association (EHRA), European Cardiac Arrhythmia Society
(ECAS), American College of Cardiology (ACC), American Heart Association (AHA), Society
of Thoracic Surgeons (STS)</collab><article-title>HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation
of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up.
A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation
of atrial fibrillation</article-title><source>Heart Rhythm</source><year>2007</year><volume>4</volume><fpage>816</fpage><lpage>861</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.hrthm.2007.04.005">doi:10.1016/j.hrthm.2007.04.005</ext-link></comment><pub-id pub-id-type="pmid">17556213</pub-id></element-citation></ref><ref id="EHS290C7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gammie</surname><given-names>JS</given-names></name><name><surname>Haddad</surname><given-names>M</given-names></name><name><surname>Milford-Beland</surname><given-names>S</given-names></name><name><surname>Welke</surname><given-names>KF</given-names></name><name><surname>Ferguson</surname><given-names>TB</given-names><suffix>Jr</suffix></name><name><surname>O'Brien</surname><given-names>SM</given-names></name><name><surname>Griffith</surname><given-names>BP</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name></person-group><article-title>Atrial fibrillation correction surgery: lessons from the Society of
Thoracic Surgeons National Cardiac Database</article-title><source>Ann Thorac Surg</source><year>2008</year><volume>85</volume><fpage>909</fpage><lpage>914</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.athoracsur.2007.10.097">doi:10.1016/j.athoracsur.2007.10.097</ext-link></comment><pub-id pub-id-type="pmid">18291169</pub-id></element-citation></ref><ref id="EHS290C8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abreu Filho</surname><given-names>CAC</given-names></name><name><surname>Lisboa</surname><given-names>LAF</given-names></name><name><surname>Dallan</surname><given-names>LAO</given-names></name><name><surname>Spina</surname><given-names>GS</given-names></name><name><surname>Grinberg</surname><given-names>M</given-names></name><name><surname>Scanavacca</surname><given-names>M</given-names></name><name><surname>Sosa</surname><given-names>EA</given-names></name><name><surname>Ramires</surname><given-names>JAF</given-names></name><name><surname>Oliveira</surname><given-names>SA</given-names></name></person-group><article-title>Effectiveness of the Maze procedure using cooled-tip radiofrequency
ablation in patients with permanent atrial fibrillation and rheumatic mitral valve
disease</article-title><source>Circulation</source><year>2005</year><volume>112</volume><issue>Suppl. 9</issue><fpage>I-20</fpage><lpage>I-25</lpage><pub-id pub-id-type="pmid">16159816</pub-id></element-citation></ref><ref id="EHS290C9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deneke</surname><given-names>T</given-names></name><name><surname>Khargi</surname><given-names>K</given-names></name><name><surname>Grewe</surname><given-names>PH</given-names></name><name><surname>Laczkovics</surname><given-names>A</given-names></name><name><surname>von Dryander</surname><given-names>S</given-names></name><name><surname>Lawo</surname><given-names>T</given-names></name><name><surname>Muller</surname><given-names>KM</given-names></name><name><surname>Lemke</surname><given-names>B</given-names></name></person-group><article-title>Efficacy of an additional MAZE procedure using cooled-tip radiofrequency
ablation in patients with chronic atrial fibrillation and mitral valve disease. A
randomized, prospective trial</article-title><source>Eur Heart J</source><year>2002</year><volume>23</volume><fpage>558</fpage><lpage>566</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1053/euhj.2001.2841">doi:10.1053/euhj.2001.2841</ext-link></comment><pub-id pub-id-type="pmid">11922646</pub-id></element-citation></ref><ref id="EHS290C10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doukas</surname><given-names>G</given-names></name><name><surname>Samani</surname><given-names>NJ</given-names></name><name><surname>Alexiou</surname><given-names>C</given-names></name><name><surname>Oc</surname><given-names>M</given-names></name><name><surname>Chin</surname><given-names>DT</given-names></name><name><surname>Stafford</surname><given-names>PG</given-names></name><name><surname>Ng</surname><given-names>LL</given-names></name><name><surname>Spyt</surname><given-names>TJ</given-names></name></person-group><article-title>Left atrial radiofrequency ablation during mitral valve surgery for
continuous atrial fibrillation: a randomized controlled trial</article-title><source>JAMA</source><year>2005</year><volume>294</volume><fpage>2323</fpage><lpage>2329</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jama.294.18.2323">doi:10.1001/jama.294.18.2323</ext-link></comment><pub-id pub-id-type="pmid">16278360</pub-id></element-citation></ref><ref id="EHS290C11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuetz</surname><given-names>A</given-names></name><name><surname>Schulze</surname><given-names>CJ</given-names></name><name><surname>Sarvanakis</surname><given-names>KK</given-names></name><name><surname>Mair</surname><given-names>H</given-names></name><name><surname>Plazer</surname><given-names>H</given-names></name><name><surname>Kilger</surname><given-names>E</given-names></name><name><surname>Reichart</surname><given-names>B</given-names></name><name><surname>Wildhirt</surname><given-names>SM</given-names></name></person-group><article-title>Surgical treatment of permanent atrial fibrillation using microwave energy
ablation: a prospective randomized clinical trial</article-title><source>Eur J Cardiothorac Surg</source><year>2003</year><volume>24</volume><fpage>475</fpage><lpage>480</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1010-7940(03)00377-4">doi:10.1016/S1010-7940(03)00377-4</ext-link></comment><pub-id pub-id-type="pmid">14500062</pub-id></element-citation></ref><ref id="EHS290C12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blomstrom-Lundqvist</surname><given-names>C</given-names></name><name><surname>Johansson</surname><given-names>B</given-names></name><name><surname>Berglin</surname><given-names>E</given-names></name><name><surname>Nilsson</surname><given-names>L</given-names></name><name><surname>Jensen</surname><given-names>SM</given-names></name><name><surname>Thelin</surname><given-names>S</given-names></name><name><surname>Holmgren</surname><given-names>A</given-names></name><name><surname>Edvardsson</surname><given-names>N</given-names></name><name><surname>K&#x000e4;llner</surname><given-names>G</given-names></name><name><surname>Blomstr&#x000f6;m</surname><given-names>P</given-names></name></person-group><article-title>A randomized double-blind study of epicardial left atrial cryoablation for
permanent atrial fibrillation in patients undergoing mitral valve surgery: the SWEDish
Multicentre Atrial Fibrillation study (SWEDMAF)</article-title><source>Eur Heart J</source><year>2007</year><volume>28</volume><fpage>2902</fpage><lpage>2908</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/eurheartj/ehm378">doi:10.1093/eurheartj/ehm378</ext-link></comment><pub-id pub-id-type="pmid">17984136</pub-id></element-citation></ref><ref id="EHS290C13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chevalier</surname><given-names>P</given-names></name><name><surname>Leizorovicz</surname><given-names>A</given-names></name><name><surname>Maureira</surname><given-names>P</given-names></name><name><surname>Carteaux</surname><given-names>JP</given-names></name><name><surname>Corbineau</surname><given-names>H</given-names></name><name><surname>Caus</surname><given-names>T</given-names></name><name><surname>DeBreyne</surname><given-names>B</given-names></name><name><surname>Mabot</surname><given-names>P</given-names></name><name><surname>Dechillou</surname><given-names>C</given-names></name><name><surname>Deharo</surname><given-names>JC</given-names></name><name><surname>Barry</surname><given-names>S</given-names></name><name><surname>Touboul</surname><given-names>P</given-names></name><name><surname>Villemot</surname><given-names>JP</given-names></name><name><surname>Obadia</surname><given-names>JF</given-names></name></person-group><article-title>Left atrial radiofrequency ablation during mitral valve surgery: a
prospective randomized multicentre study (SAFIR)</article-title><source>Arch Cardiovasc Dis</source><year>2009</year><volume>102</volume><fpage>769</fpage><lpage>775</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.acvd.2009.08.010">doi:10.1016/j.acvd.2009.08.010</ext-link></comment><pub-id pub-id-type="pmid">19944393</pub-id></element-citation></ref><ref id="EHS290C14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lima</surname><given-names>GG</given-names></name><name><surname>Kalil</surname><given-names>RAK</given-names></name><name><surname>Leiria</surname><given-names>TLL</given-names></name><name><surname>Hatem</surname><given-names>DM</given-names></name><name><surname>Kruse</surname><given-names>CL</given-names></name><name><surname>Abrahao</surname><given-names>R</given-names></name><name><surname>Sant'anna</surname><given-names>JRM</given-names></name><name><surname>Prates</surname><given-names>PR</given-names></name><name><surname>Nesralla</surname><given-names>IA</given-names></name></person-group><article-title>Randomized study of surgery for patients with permanent atrial fibrillation
as a result of mitral valve disease</article-title><source>Ann Thorac Surg</source><year>2004</year><volume>77</volume><fpage>2089</fpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.athoracsur.2003.11.018">doi:10.1016/j.athoracsur.2003.11.018</ext-link></comment><pub-id pub-id-type="pmid">15172273</pub-id></element-citation></ref><ref id="EHS290C15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Oppell</surname><given-names>U</given-names></name><name><surname>Masani</surname><given-names>N</given-names></name><name><surname>O'Callaghan</surname><given-names>P</given-names></name><name><surname>Wheeler</surname><given-names>R</given-names></name><name><surname>Dimitrakakis</surname><given-names>G</given-names></name><name><surname>Schiffelers</surname><given-names>S</given-names></name></person-group><article-title>Mitral valve surgery plus concomitant atrial fibrillation ablation is
superior to mitral valve surgery alone with an intensive rhythm control
strategy</article-title><source>Eur J Cardiothorac Surg</source><year>2009</year><volume>35</volume><fpage>641</fpage><lpage>650</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejcts.2008.12.042">doi:10.1016/j.ejcts.2008.12.042</ext-link></comment><pub-id pub-id-type="pmid">19233678</pub-id></element-citation></ref><ref id="EHS290C16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albrecht</surname><given-names>A</given-names></name><name><surname>Kalil</surname><given-names>RAK</given-names></name><name><surname>Schuch</surname><given-names>L</given-names></name><name><surname>Abrahao</surname><given-names>R</given-names></name><name><surname>Sant'Anna</surname><given-names>JRM</given-names></name><name><surname>de Lima</surname><given-names>G</given-names></name><name><surname>Nesralla</surname><given-names>IA</given-names></name></person-group><article-title>Randomized study of surgical isolation of the pulmonary veins for
correction of permanent atrial fibrillation associated with mitral valve
disease</article-title><source>J Thorac Cardiovasc Surg</source><year>2009</year><volume>138</volume><fpage>454</fpage><lpage>459</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jtcvs.2009.04.023">doi:10.1016/j.jtcvs.2009.04.023</ext-link></comment><pub-id pub-id-type="pmid">19619795</pub-id></element-citation></ref><ref id="EHS290C17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNamara</surname><given-names>RL</given-names></name><name><surname>Brass</surname><given-names>LM</given-names></name><name><surname>Drozda</surname><given-names>JP</given-names><suffix>Jr</suffix></name><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Halperin</surname><given-names>JL</given-names></name><name><surname>Kerr</surname><given-names>CR</given-names></name><name><surname>L&#x000e9;vy</surname><given-names>S</given-names></name><name><surname>Malenka</surname><given-names>DJ</given-names></name><name><surname>Mittal</surname><given-names>S</given-names></name><name><surname>Pelosi</surname><given-names>F</given-names><suffix>Jr</suffix></name><name><surname>Rosenberg</surname><given-names>Y</given-names></name><name><surname>Stryer</surname><given-names>D</given-names></name><name><surname>Wyse</surname><given-names>DG</given-names></name><name><surname>Radford</surname><given-names>MJ</given-names></name><name><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></name><name><surname>Grover</surname><given-names>FL</given-names></name><name><surname>Heidenreich</surname><given-names>PA</given-names></name><name><surname>Malenka</surname><given-names>DJ</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name><name><surname>Redberg</surname><given-names>RF</given-names></name></person-group><collab>Endorsed by the Mediterranean Society of Pacing and Electrophysiology, WRITING
COMMITTEE MEMBERS</collab><article-title>ACC/AHA key data elements and definitions for measuring the clinical
management and outcomes of patients with atrial fibrillation: A Report of the American
College of Cardiology/American Heart Association Task Force on Clinical Data Standards
(Writing Committee to Develop Data Standards on Atrial Fibrillation)</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>3223</fpage><lpage>3324</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/01.CIR.0000131893.41821.D1">doi:10.1161/01.CIR.0000131893.41821.D1</ext-link></comment><pub-id pub-id-type="pmid">15226233</pub-id></element-citation></ref><ref id="EHS290C18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shemin</surname><given-names>R</given-names></name><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Gillinov</surname><given-names>A</given-names></name><name><surname>Blackstone</surname><given-names>E</given-names></name><name><surname>Bridges</surname><given-names>C</given-names></name></person-group><article-title>Guidelines for reporting data and outcomes for the surgical treatment of
atrial fibrillation</article-title><source>Ann Thorac Surg</source><year>2007</year><volume>83</volume><fpage>1225</fpage><lpage>1230</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.athoracsur.2006.11.094">doi:10.1016/j.athoracsur.2006.11.094</ext-link></comment><pub-id pub-id-type="pmid">17307507</pub-id></element-citation></ref><ref id="EHS290C19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchhof</surname><given-names>P</given-names></name><name><surname>Auricchio</surname><given-names>A</given-names></name><name><surname>Bax</surname><given-names>J</given-names></name><name><surname>Crijns</surname><given-names>H</given-names></name><name><surname>Camm</surname><given-names>J</given-names></name><name><surname>Diener</surname><given-names>HC</given-names></name><name><surname>Goette</surname><given-names>A</given-names></name><name><surname>Hindricks</surname><given-names>G</given-names></name><name><surname>Hohnloser</surname><given-names>S</given-names></name><name><surname>Kappenberger</surname><given-names>L</given-names></name><name><surname>Kuck</surname><given-names>KH</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name><name><surname>Olsson</surname><given-names>B</given-names></name><name><surname>Meinertz</surname><given-names>T</given-names></name><name><surname>Priori</surname><given-names>S</given-names></name><name><surname>Ravens</surname><given-names>U</given-names></name><name><surname>Steinbeck</surname><given-names>G</given-names></name><name><surname>Svernhage</surname><given-names>E</given-names></name><name><surname>Tijssen</surname><given-names>J</given-names></name><name><surname>Vincent</surname><given-names>A</given-names></name><name><surname>Breithardt</surname><given-names>G</given-names></name></person-group><article-title>Outcome parameters for trials in atrial fibrillation: executive summary.
Recommendations from a consensus conference organized by the German Atrial Fibrillation
Competence NETwork (AFNET) and the European Heart Rhythm Association
(EHRA)</article-title><source>Eur Heart J</source><year>2007</year><volume>28</volume><fpage>2803</fpage><lpage>2817</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/eurheartj/ehm358">doi:10.1093/eurheartj/ehm358</ext-link></comment><pub-id pub-id-type="pmid">17897924</pub-id></element-citation></ref><ref id="EHS290C20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damiano</surname><given-names>RJ</given-names><suffix>Jr</suffix></name><name><surname>Gaynor</surname><given-names>SL</given-names></name><name><surname>Bailey</surname><given-names>M</given-names></name><name><surname>Prasad</surname><given-names>S</given-names></name><name><surname>Cox</surname><given-names>JL</given-names></name><name><surname>Boineau</surname><given-names>JP</given-names></name><name><surname>Schuessler</surname><given-names>RP</given-names></name></person-group><article-title>The long-term outcome of patients with coronary disease and atrial
fibrillation undergoing the Cox maze procedure</article-title><source>J Thorac Cardiovasc Surg</source><year>2003</year><volume>126</volume><fpage>2016</fpage><lpage>2021</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jtcvs.2003.07.006">doi:10.1016/j.jtcvs.2003.07.006</ext-link></comment><pub-id pub-id-type="pmid">14688721</pub-id></element-citation></ref><ref id="EHS290C21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>SM</given-names></name><name><surname>Maniar</surname><given-names>HS</given-names></name><name><surname>Camillo</surname><given-names>CJ</given-names></name><name><surname>Schuessler</surname><given-names>RB</given-names></name><name><surname>Boineau</surname><given-names>JP</given-names></name><name><surname>Sundt</surname><given-names>TM</given-names><suffix>III</suffix></name><name><surname>Cox</surname><given-names>JL</given-names></name><name><surname>Damiano</surname><given-names>RJ</given-names><suffix>Jr</suffix></name></person-group><article-title>The Cox maze III procedure for atrial fibrillation: long-term efficacy in
patients undergoing lone versus concomitant procedures</article-title><source>J Thorac Cardiovasc Surg</source><year>2003</year><volume>126</volume><fpage>1822</fpage><lpage>1827</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0022-5223(03)01287-X">doi:10.1016/S0022-5223(03)01287-X</ext-link></comment><pub-id pub-id-type="pmid">14688693</pub-id></element-citation></ref><ref id="EHS290C22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bando</surname><given-names>K</given-names></name><name><surname>Kobayashi</surname><given-names>J</given-names></name><name><surname>Sasako</surname><given-names>Y</given-names></name><name><surname>Tagusari</surname><given-names>O</given-names></name><name><surname>Niwaya</surname><given-names>K</given-names></name><name><surname>Kitamura</surname><given-names>S</given-names></name></person-group><article-title>Effect of maze procedure in patients with atrial fibrillation undergoing
valve replacement</article-title><source>J Heart Valve Dis</source><year>2002</year><volume>11</volume><fpage>719</fpage><lpage>724</lpage><pub-id pub-id-type="pmid">12358411</pub-id></element-citation></ref><ref id="EHS290C23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ad</surname><given-names>N</given-names></name><name><surname>Cox</surname><given-names>JL</given-names></name></person-group><article-title>Stroke prevention as an indication for the Maze procedure in the treatment
of atrial fibrillation</article-title><source>Semin Thorac Cardiovasc Surg</source><year>2000</year><volume>12</volume><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">10746924</pub-id></element-citation></ref><ref id="EHS290C24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khargi</surname><given-names>K</given-names></name><name><surname>Hutten</surname><given-names>BA</given-names></name><name><surname>Lemke</surname><given-names>B</given-names></name><name><surname>Deneke</surname><given-names>T</given-names></name></person-group><article-title>Surgical treatment of atrial fibrillation; a systematic
review</article-title><source>Eur J Cardiothorac Surg</source><year>2005</year><volume>27</volume><fpage>258</fpage><lpage>265</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejcts.2004.11.003">doi:10.1016/j.ejcts.2004.11.003</ext-link></comment><pub-id pub-id-type="pmid">15691679</pub-id></element-citation></ref><ref id="EHS290C25"><label>25</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Voeller</surname><given-names>RK</given-names></name><name><surname>Schuessler</surname><given-names>RB</given-names></name><name><surname>Damiano</surname><given-names>RJ</given-names><suffix>Jr</suffix></name></person-group><person-group person-group-type="editor"><name><surname>Cohn</surname><given-names>Lh</given-names></name></person-group><article-title>Surgical treatment of atrial fibrillation</article-title><source>Cardiac Surgery in the Adult</source><year>2008</year><edition>3rd ed.</edition><publisher-loc>New York</publisher-loc><publisher-name>McGraw-Hill</publisher-name><fpage>1375</fpage><lpage>1394</lpage></element-citation></ref><ref id="EHS290C26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camm</surname><given-names>CF</given-names></name><name><surname>Nagendran</surname><given-names>M</given-names></name><name><surname>Xiu</surname><given-names>PY</given-names></name><name><surname>Maruthappu</surname><given-names>M</given-names></name></person-group><article-title>How effective is cryoablation for atrial fibrillation during concomitant
cardiac surgery?</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2011</year><volume>13</volume><fpage>410</fpage><lpage>414</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1510/icvts.2011.271676">doi:10.1510/icvts.2011.271676</ext-link></comment><pub-id pub-id-type="pmid">21791522</pub-id></element-citation></ref><ref id="EHS290C27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gammie</surname><given-names>JS</given-names></name><name><surname>Didolkar</surname><given-names>P</given-names></name><name><surname>Krowsoski</surname><given-names>LS</given-names></name><name><surname>Santos</surname><given-names>MJ</given-names></name><name><surname>Toran</surname><given-names>AJ</given-names></name><name><surname>Young</surname><given-names>CA</given-names></name><name><surname>Griffith</surname><given-names>BP</given-names></name><name><surname>Shorofsky</surname><given-names>SR</given-names></name><name><surname>Vander Salm</surname><given-names>TJ</given-names></name></person-group><article-title>Intermediate-term outcomes of surgical atrial fibrillation correction with
the cryomaze procedure</article-title><source>Ann Thorac Surg</source><year>2009</year><volume>87</volume><fpage>1452</fpage><lpage>1459</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.athoracsur.2009.02.008">doi:10.1016/j.athoracsur.2009.02.008</ext-link></comment><pub-id pub-id-type="pmid">19379884</pub-id></element-citation></ref><ref id="EHS290C28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinek</surname><given-names>M</given-names></name><name><surname>Aichinger</surname><given-names>J</given-names></name><name><surname>Nesser</surname><given-names>HJ</given-names></name><name><surname>Ziegler</surname><given-names>PD</given-names></name><name><surname>Purerfellner</surname><given-names>H</given-names></name></person-group><article-title>New insights into long-term follow-up of atrial fibrillation ablation: full
disclosure by an implantable pacemaker device</article-title><source>J Cardiovasc Electrophysiol</source><year>2007</year><volume>18</volume><fpage>818</fpage><lpage>823</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1540-8167.2007.00883.x">doi:10.1111/j.1540-8167.2007.00883.x</ext-link></comment><pub-id pub-id-type="pmid">17573835</pub-id></element-citation></ref><ref id="EHS290C29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ad</surname><given-names>N</given-names></name><name><surname>Henry</surname><given-names>L</given-names></name><name><surname>Hunt</surname><given-names>S</given-names></name><name><surname>Holmes</surname><given-names>SD</given-names></name></person-group><article-title>Do we increase the operative risk by adding the Cox Maze III procedure to
aortic valve replacement and coronary artery bypass surgery?</article-title><source>J Thorac Cardiovasc Surg</source><year>2012</year><volume>143</volume><fpage>936</fpage><lpage>944</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jtcvs.2011.12.018">doi:10.1016/j.jtcvs.2011.12.018</ext-link></comment><pub-id pub-id-type="pmid">22244503</pub-id></element-citation></ref><ref id="EHS290C30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bando</surname><given-names>K</given-names></name><name><surname>Kobayashi</surname><given-names>J</given-names></name><name><surname>Kosakai</surname><given-names>Y</given-names></name><name><surname>Hirata</surname><given-names>M</given-names></name><name><surname>Sasako</surname><given-names>Y</given-names></name><name><surname>Nakatani</surname><given-names>S</given-names></name><name><surname>Yagihara</surname><given-names>T</given-names></name><name><surname>Kitamura</surname><given-names>S</given-names></name></person-group><article-title>Impact of Cox-Maze procedure on outcome in patients with atrial
fibrillation and mitral valve disease</article-title><source>J Thorac Cardiovasc Surg</source><year>2002</year><volume>124</volume><fpage>575</fpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1067/mtc.2002.124392">doi:10.1067/mtc.2002.124392</ext-link></comment><pub-id pub-id-type="pmid">12202874</pub-id></element-citation></ref><ref id="EHS290C31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louagie</surname><given-names>Y</given-names></name><name><surname>Buche</surname><given-names>M</given-names></name><name><surname>Eucher</surname><given-names>P</given-names></name><name><surname>Schoevaerdts</surname><given-names>JC</given-names></name><name><surname>Gerard</surname><given-names>M</given-names></name><name><surname>Jamart</surname><given-names>J</given-names></name><name><surname>Blommaert</surname><given-names>D</given-names></name></person-group><article-title>Improved patient survival with concomitant Cox Maze III procedure compared
with heart surgery alone</article-title><source>Ann Thorac Surg</source><year>2009</year><volume>87</volume><fpage>440</fpage><lpage>446</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.athoracsur.2008.10.001">doi:10.1016/j.athoracsur.2008.10.001</ext-link></comment><pub-id pub-id-type="pmid">19161756</pub-id></element-citation></ref><ref id="EHS290C32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunderland</surname><given-names>N</given-names></name><name><surname>Maruthappu</surname><given-names>M</given-names></name><name><surname>Nagendran</surname><given-names>M</given-names></name></person-group><article-title>What size of left atrium significantly impairs the success of maze surgery
for atrial fibrillation?</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2011</year><volume>13</volume><fpage>332</fpage><lpage>338</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1510/icvts.2011.271999">doi:10.1510/icvts.2011.271999</ext-link></comment><pub-id pub-id-type="pmid">21632865</pub-id></element-citation></ref><ref id="EHS290C33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Je</surname><given-names>HG</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Jung</surname><given-names>SH</given-names></name><name><surname>Choo</surname><given-names>SJ</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Yun</surname><given-names>SC</given-names></name><name><surname>Chung</surname><given-names>CH</given-names></name></person-group><article-title>Risk factors analysis on failure of maze procedure: mid-term
results</article-title><source>Eur J Cardiothorac Surg</source><year>2009</year><volume>36</volume><fpage>272</fpage><lpage>279</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejcts.2009.02.058">doi:10.1016/j.ejcts.2009.02.058</ext-link></comment><pub-id pub-id-type="pmid">19409801</pub-id></element-citation></ref><ref id="EHS290C34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>JB</given-names></name><name><surname>Cho</surname><given-names>WC</given-names></name><name><surname>Chung</surname><given-names>CH</given-names></name><name><surname>Jung</surname><given-names>SH</given-names></name><name><surname>Choo</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name></person-group><article-title>The influence of age on atrial fibrillation recurrence after the maze
procedure in patients with giant left atrium</article-title><source>J Thorac Cardiovasc Surg</source><year>2011</year><volume>141</volume><fpage>1015</fpage><lpage>1019</lpage><pub-id pub-id-type="pmid">20934727</pub-id></element-citation></ref></ref-list></back></article>